JMP Securities Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $397
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains an Outperform rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $351 to $397.
March 15, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities raises Madrigal Pharmaceuticals' price target to $397, maintaining an Outperform rating.
The increase in price target by JMP Securities suggests a positive outlook on Madrigal Pharmaceuticals' stock, likely due to strong company fundamentals or market potential. This analyst endorsement can boost investor confidence, potentially leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100